London UK, May 4th 2016: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has been shortlisted to present at the prestigious Innovate UK Health & Life Science Investment Showcase. The showcase is a new vehicle managed by Innovate UK to connect the UK’s most innovative early-stage companies with investors.
Dr Salman Rahman, CEO and co-founder of Vasgen said: “We are very pleased to have scored sufficiently well to have been shortlisted by Innovate UK to pitch at the investment showcase later this month. This welcome news is further validation of our innovative antibody platform and the potential of our lead therapeutic programme targeting ADAM15 to improve vision in patients with ocular neovascular and hyperpermeability disorders.”
-Ends-
Notes to Editors:
Vasgen
Vasgen Limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMP®, a novel antibody-based approach allowing development of highly selective inhibitors of metzincin metalloproteinases with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149
Innovate UK
Innovate UK (formerly the Technology Strategy Board) is the UK’s innovation agency. It’s goal is to accelerate economic growth by stimulating and supporting business-led innovation. More information is available at www.innovateuk.org